183 related articles for article (PubMed ID: 35735437)
21. Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis.
Watkins AJ; Huang Y; Ye H; Chanudet E; Johnson N; Hamoudi R; Liu H; Dong G; Attygalle A; McPhail ED; Law ME; Isaacson PG; de Leval L; Wotherspoon A; Du MQ
J Pathol; 2010 Mar; 220(4):461-74. PubMed ID: 20077527
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
Wong KY; Chim CS
J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
[TBL] [Abstract][Full Text] [Related]
23. Splenic marginal zone lymphoma with monoclonal IgG: A case report.
Zhang X; Ren S; Zhang N; Wang X; Qiu L; Sun H; Yi H; Fan F
Medicine (Baltimore); 2024 Feb; 103(6):e37158. PubMed ID: 38335376
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
25. A marginal zone pattern may be found in different varieties of non-Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma.
Piris MA; Mollejo M; Campo E; Menárguez J; Flores T; Isaacson PG
Histopathology; 1998 Sep; 33(3):230-9. PubMed ID: 9777389
[TBL] [Abstract][Full Text] [Related]
26. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?
Ponzoni M; Kanellis G; Pouliou E; Baliakas P; Scarfò L; Ferreri AJ; Doglioni C; Bikos V; Dagklis A; Anagnostopoulos A; Ghia P; Stamatopoulos K; Papadaki T
Am J Surg Pathol; 2012 Nov; 36(11):1609-18. PubMed ID: 23073320
[TBL] [Abstract][Full Text] [Related]
28. Unraveling the genetics of transformed splenic marginal zone lymphoma.
Grau M; López C; Navarro A; Frigola G; Nadeu F; Clot G; Bastidas-Mora G; Alcoceba M; Baptista MJ; Blanes M; Colomer D; Costa D; Domingo-Domènech E; Enjuanes A; Escoda L; Forcada P; Giné E; Lopez-Guerra M; Ramón O; Rivas-Delgado A; Vicente Folch L; Wotherspoon A; Climent F; Campo E; López-Guillermo A; Matutes E; Beà S
Blood Adv; 2023 Jul; 7(14):3695-3709. PubMed ID: 36995085
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.
Tang X; Zou W; Peng P; Bai Y
Clin Exp Med; 2022 May; 22(2):161-171. PubMed ID: 34224006
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.
Scott LJ
Target Oncol; 2019 Oct; 14(5):493-504. PubMed ID: 31542870
[TBL] [Abstract][Full Text] [Related]
31. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
32. Possible novel agents in marginal zone lymphoma.
Zinzani PL; Broccoli A
Best Pract Res Clin Haematol; 2017; 30(1-2):149-157. PubMed ID: 28288710
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
34. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS; Roberts AW; Seymour JF; Pagel JM; Kahl BS; Wierda WG; Puvvada S; Kipps TJ; Anderson MA; Salem AH; Dunbar M; Zhu M; Peale F; Ross JA; Gressick L; Desai M; Kim SY; Verdugo M; Humerickhouse RA; Gordon GB; Gerecitano JF
J Clin Oncol; 2017 Mar; 35(8):826-833. PubMed ID: 28095146
[TBL] [Abstract][Full Text] [Related]
35. Splenic marginal zone lymphoma: from genetics to management.
Arcaini L; Rossi D; Paulli M
Blood; 2016 Apr; 127(17):2072-81. PubMed ID: 26989207
[TBL] [Abstract][Full Text] [Related]
36. Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Deng R; Gibiansky L; Lu T; Li X; Lu D; Li C; Girish S; Wang J; Boyer M; Shankar N; Humphrey K; Freise KJ; Salem AH; Seymour JF; Kater AP; Miles D
Leuk Lymphoma; 2020 Jan; 61(1):56-65. PubMed ID: 31549889
[TBL] [Abstract][Full Text] [Related]
37. Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
Freise KJ; Jones AK; Eckert D; Mensing S; Wong SL; Humerickhouse RA; Awni WM; Salem AH
Clin Pharmacokinet; 2017 May; 56(5):515-523. PubMed ID: 27638334
[TBL] [Abstract][Full Text] [Related]
38. Primary nodal marginal zone lymphomas of splenic and MALT type.
Campo E; Miquel R; Krenacs L; Sorbara L; Raffeld M; Jaffe ES
Am J Surg Pathol; 1999 Jan; 23(1):59-68. PubMed ID: 9888704
[TBL] [Abstract][Full Text] [Related]
39. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
40. Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
.
Brumbaugh Paradis H; Alter D; Llerandi D
Clin J Oncol Nurs; 2017 Oct; 21(5):604-610. PubMed ID: 28945711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
